Amphista to initiate its first clinical trial for AMX-883, a potent, orally bioavailable DCAF16-dependent degrader of BRD9, for acute myeloid leukaemia (AML) in H2 2026 The Phase 1 monotherapy dose-escalation...
Gilde Healthcare company Amphista Therapeutics announces FDA clearance of IND application for AMX-883, its lead Targeted Glue™ degrader for acute myeloid leukaemia
Amphista to initiate its first clinical trial for AMX-883, a potent, orally bioavailable DCAF16-dependent degrader of BRD9, for acute myeloid leukaemia (AML) in H2 2026 The Phase 1 monotherapy dose-escalation...
June 11, 2026
Gilde Healthcare appoints Matthew Stork as CEO and Maarten Jaspers as Finance Director of its neuroimaging technology group
The neuroimaging group, consisting of Artinis and NIRx, leading in functional Near-Infrared Spectroscopy (fNIRS) solutions, has appointed Matthew Stork as Chief Executive Officer (CEO) and Maarten Jaspers as Finance Director....
February 5, 2026
Gilde Healthcare launches Climate Solutions fund realizing initial close at €250M
With commitments from international pension funds, banks, fund-of-funds, endowments and family offices, Gilde Healthcare realizes an initial close at €250 million Expansion into Climate Solutions builds on Gilde Healthcare’s track...
February 18, 2026
Gilde Healthcare company Amphista Therapeutics announces FDA clearance of IND application for AMX-883, its lead Targeted Glue™ degrader for acute myeloid leukaemia
Amphista to initiate its first clinical trial for AMX-883, a potent, orally bioavailable DCAF16-dependent degrader of BRD9, for acute myeloid leukaemia (AML) in H2 2026 The Phase 1 monotherapy dose-escalation...
June 11, 2026
Filter & search
Fund strategy:
Loading...
These were all articles
8684851dec